
    
      LBH589 (20 mg PO) will be administered three times a week on Monday, Wednesday and Friday.
      Treatment will be given over 21 days followed by a 7 day rest period and repeated every 28
      days. Patients will be assessed for toxicity on an ongoing basis and disease assessment will
      be determined every 2 treatment cycles (8 weeks). Patients will be allowed to continue on
      treatment for a maximum of eight four week treatment cycles. Treatment will be discontinued
      if there is evidence of disease progression, unacceptable toxicity and/or at the discretion
      of the investigator.
    
  